VistaGen Therapeutics Inc (VTGN) - Net Assets
Based on the latest financial reports, VistaGen Therapeutics Inc (VTGN) has net assets worth $50.92 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($65.06 Million) and total liabilities ($14.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of VistaGen Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $50.92 Million |
| % of Total Assets | 78.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -23.47% |
| 10-Year Change | N/A |
| Growth Volatility | 440.91 |
VistaGen Therapeutics Inc - Net Assets Trend (2008–2025)
This chart illustrates how VistaGen Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of VistaGen Therapeutics Inc for the complete picture of this company's asset base.
Annual Net Assets for VistaGen Therapeutics Inc (2008–2025)
The table below shows the annual net assets of VistaGen Therapeutics Inc from 2008 to 2025. For live valuation and market cap data, see VTGN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $70.39 Million | -38.41% |
| 2024-03-31 | $114.29 Million | +846.08% |
| 2023-03-31 | $12.08 Million | -81.33% |
| 2022-03-31 | $64.72 Million | -29.64% |
| 2021-03-31 | $91.98 Million | +1705.38% |
| 2020-03-31 | $-5.73 Million | -180.98% |
| 2019-03-31 | $7.08 Million | +2.29% |
| 2018-03-31 | $6.92 Million | +1023.19% |
| 2017-03-31 | $615.80K | +120.68% |
| 2016-03-31 | $-2.98 Million | +85.51% |
| 2015-03-31 | $-20.54 Million | -60.49% |
| 2014-03-31 | $-12.80 Million | -1.94% |
| 2013-03-31 | $-12.56 Million | -120.07% |
| 2012-03-31 | $-5.71 Million | -570460.00% |
| 2011-03-31 | $-1.00K | -706.45% |
| 2010-03-31 | $-124.00 | -100.61% |
| 2009-03-31 | $20.37K | +14151.03% |
| 2008-03-31 | $-145.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to VistaGen Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40762175500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $29.00K | 0.04% |
| Other Comprehensive Income | $5.00K | 0.01% |
| Other Components | $477.99 Million | 679.06% |
| Total Equity | $70.39 Million | 100.00% |
VistaGen Therapeutics Inc Competitors by Market Cap
The table below lists competitors of VistaGen Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanogroup SA
WAR:NNG
|
$22.04 Million |
|
Sungwoo Techron. Co.Ltd
KQ:045300
|
$22.05 Million |
|
SAMJIN Co. Ltd
KQ:032750
|
$22.05 Million |
|
Japan Gold Corp
V:JG
|
$22.05 Million |
|
Ras Technology Holdings Ltd
AU:RTH
|
$22.02 Million |
|
Romcarbon Sa B
RO:ROCE
|
$22.01 Million |
|
Swoop Holdings Ltd
AU:SWP
|
$22.01 Million |
|
Han Chang Pape
KO:009460
|
$22.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VistaGen Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 114,286,000 to 70,390,000, a change of -43,896,000 (-38.4%).
- Net loss of 51,418,000 reduced equity.
- New share issuances of 3,009,000 increased equity.
- Other comprehensive income increased equity by 5,000.
- Other factors increased equity by 4,508,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-51.42 Million | -73.05% |
| Share Issuances | $3.01 Million | +4.27% |
| Other Comprehensive Income | $5.00K | +0.01% |
| Other Changes | $4.51 Million | +6.4% |
| Total Change | $- | -38.41% |
Book Value vs Market Value Analysis
This analysis compares VistaGen Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-03-31 | $-0.01 | $0.63 | x |
| 2009-03-31 | $1.17 | $0.63 | x |
| 2010-03-31 | $-0.01 | $0.63 | x |
| 2011-03-31 | $-0.05 | $0.63 | x |
| 2012-03-31 | $-232.30 | $0.63 | x |
| 2013-03-31 | $-416.04 | $0.63 | x |
| 2014-03-31 | $-349.34 | $0.63 | x |
| 2015-03-31 | $-467.31 | $0.63 | x |
| 2016-03-31 | $-50.52 | $0.63 | x |
| 2017-03-31 | $2.45 | $0.63 | x |
| 2018-03-31 | $14.94 | $0.63 | x |
| 2019-03-31 | $7.43 | $0.63 | x |
| 2020-03-31 | $-3.92 | $0.63 | x |
| 2021-03-31 | $32.04 | $0.63 | x |
| 2022-03-31 | $9.81 | $0.63 | x |
| 2023-03-31 | $1.74 | $0.63 | x |
| 2024-03-31 | $5.90 | $0.63 | x |
| 2025-03-31 | $2.29 | $0.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VistaGen Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10579.84%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.20x
- Recent ROE (-73.05%) is above the historical average (-165.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.74K |
| 2009 | -80.57% | 0.00% | 0.00x | 1.13x | $-18.45K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.99K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.88K |
| 2012 | 0.00% | -909.66% | 3.93x | 0.00x | $-11.64 Million |
| 2013 | 0.00% | -6430.49% | 0.23x | 0.00x | $-11.63 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.69 Million |
| 2015 | 0.00% | 0.00% | -0.50x | 0.00x | $-11.83 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.92 Million |
| 2017 | -1665.39% | -820.44% | 0.34x | 6.03x | $-10.32 Million |
| 2018 | -207.41% | 0.00% | 0.00x | 1.63x | $-15.04 Million |
| 2019 | -347.55% | 0.00% | 0.00x | 1.98x | $-25.30 Million |
| 2020 | 0.00% | -6219.76% | 0.06x | 0.00x | $-20.20 Million |
| 2021 | -19.50% | -1646.09% | 0.01x | 1.18x | $-27.13 Million |
| 2022 | -73.80% | -4307.19% | 0.01x | 1.15x | $-54.23 Million |
| 2023 | -490.46% | 0.00% | -0.01x | 1.75x | $-60.46 Million |
| 2024 | -25.69% | -2759.59% | 0.01x | 1.08x | $-40.79 Million |
| 2025 | -73.05% | -10579.84% | 0.01x | 1.20x | $-58.46 Million |
Industry Comparison
This section compares VistaGen Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VistaGen Therapeutics Inc (VTGN) | $50.92 Million | 0.00% | 0.28x | $22.02 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more